ALS Therapy Development Foundation
-
Amyotrophic Lateral Sclerosis (ALS)
-
The institute researches new treatments for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, which affects 350,000 people worldwide. ALS is is a progressive disease with no cure or effective treatment, which attacks motor neurons in the brain and spinal cord, causing muscles to waste away. Patients live an average of two-to-five years after diagnosis.
Therapy
-
There is currently little therapy and no cure for ALS. Currently there is only a single therapy approved for treating ALS progression, the drug Rilutek (riluzole). The medical community estimates its benefits as modest---extending patient survival by three months. The institute has discovered a molecule in animals that significantly extended the life of animals with ALS.
Founding
-
The institute was founded in 1999 by James Allen Heywood, after his brother Stephen was diagnosed with ALS, and is located in Cambridge, Massachusetts.
The Institute's Work
-
The institute has collaborated with dozens of academic labs and leading biotechs worldwide. The institute's industrial-scale organization allows for the development and testing of dozens of potential therapeutics each year, including those relating to gene therapy, immunology and stem-cell therapy.
Public Outreach
-
The institute relies on donations to do its work. The institute's website hosts a public forum on the disease and its research which allows visitors to ask researchers a question. Some of the funding for the institute comes from the ALS community---nonprofit groups, patients and medical facilities. Fund-raising events are posted on its website. A special section on its website provides fund-raising tools, including event development tools and marketing materials.
-